What is Predicine?
Predicine is a biotechnology company dedicated to enhancing precision cancer therapies. Its core innovation lies in a next-generation liquid biopsy platform that provides crucial molecular insights into cancer. By analyzing blood and urine samples, Predicine enables non-invasive cancer detection and continuous monitoring. The company offers comprehensive molecular profiling assays and specialized biopharma clinical research solutions, critically supporting biomarker-driven clinical trials. Predicine's collaborative approach with leading biopharmaceutical entities aims to optimize oncology drug development and elevate patient care standards.
How much funding has Predicine raised?
Predicine has raised a total of $1.1M across 2 funding rounds:
Debt
$350K
Debt
$703K
Debt (2020): $350K with participation from PPP
Debt (2021): $703K led by PPP
Key Investors in Predicine
PPP
Public-Private Partnership
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Predicine?
With the infusion of major strategic investment and substantial enterprise-level capital, Predicine is poised for significant expansion and innovation. The company's focus on advancing its liquid biopsy technology and molecular profiling assays suggests a strategic push towards broader clinical adoption and enhanced biopharmaceutical partnerships. This backing will likely fuel further research and development, potentially leading to new diagnostic tools and therapeutic strategies in oncology. Predicine's trajectory indicates a strong commitment to improving patient outcomes through data-driven precision medicine, positioning it as a key player in the future of cancer care.
See full Predicine company page
